Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Kaibao Pharmaceutical CoSZSE:300039 -5.94%78 Altman Z2-Score is 16.11 as of Aug. 23, 2026, which is 11% above its 10-year median of 14.46. GuruFocus rates SZSE:300039 with a GF Score™ of 78/100 and a GF Value™ of ¥4.65 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 885 Drug Manufacturers companies, Shanghai Kaibao Pharmaceutical Co ranks better than 94.69% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Shanghai Kaibao Pharmaceutical Co has a Altman Z2-Score of 16.11, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score or its related term are showing as below:
SZSE:300039'
s Altman Z2-Score Range Over the Past 10 Years
Min: 9.51 Med: 14.46 Max: 18.46
Current: 16.11
During the past 13 years, Shanghai Kaibao Pharmaceutical Co's highest Altman Z2-Score was 18.46. The lowest was 9.51. And the median was 14.46.
Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Kaibao Pharmaceutical Co Altman Z2-Score Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Kaibao Pharmaceutical Co Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score falls into.
Shanghai Kaibao Pharmaceutical Co Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Shanghai Kaibao Pharmaceutical Co (SZSE:300039) has a Altman Z2-Score of 16.11 as of Aug. 23, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. This is 11% above median its historical median of 14.46. Over the past decade, Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score has ranged from 9.51 to 18.46. According to the industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #47 out of 885 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score too high?
Shanghai Kaibao Pharmaceutical Co's current Altman Z2-Score of 16.11 is 11% above median its 10-year median of 14.46. Over the past 10 years, this metric has ranged from a low of 9.51 to a high of 18.46. The Drug Manufacturers industry median Altman Z2-Score is 3.55. Shanghai Kaibao Pharmaceutical Co's value of 16.11 is 353.8% above this industry median. Based on the distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #47 out of 885 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Kaibao Pharmaceutical Co has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Kaibao Pharmaceutical Co's Altman Z2-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #47 out of 885 companies for Altman Z2-Score. This places Shanghai Kaibao Pharmaceutical Co in the top 5% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.55. Shanghai Kaibao Pharmaceutical Co's value of 16.11 is 353.8% above this benchmark. Historically, Shanghai Kaibao Pharmaceutical Co's own Altman Z2-Score has ranged from 9.51 to 18.46 over the past decade. While the company's 10-year median is 14.46 vs. the industry median of 3.55, Shanghai Kaibao Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.55, based on 885 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Kaibao Pharmaceutical Co's current Altman Z2-Score of 16.11 is 353.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Kaibao Pharmaceutical Co's current Altman Z2-Score is 16.11, which is 11% above median its own 10-year median of 14.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Kaibao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co (SZSE:300039) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.65, compared to a current price of ¥5.54 — trading 19.1% above its estimated fair value. The current Altman Z2-Score is 16.11, which is 11% above median its 10-year median of 14.46 and 353.8% above the Drug Manufacturers industry median of 3.55. Shanghai Kaibao Pharmaceutical Co's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Shanghai Kaibao Pharmaceutical Co (SZSE:300039), the current Altman Z2-Score is 16.11 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥5.54 is trading 19.1% above its estimated GF Value™ of ¥4.65.
GuruFocus considers Shanghai Kaibao Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SZSE:300039:
Altman Z2-Score: 16.11 (11% above median its 10-year median of 14.46)
GF Value™: ¥4.65 vs. price of ¥5.54 (19.1% above fair value)
Industry Position: 353.8% above the Drug Manufacturers median (#47 of 885)
No single metric tells the full story. See the SZSE:300039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
78GF Score
Get the complete analysis for SZSE:300039
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300039 has been successfully added to your 
